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Abstract
Background: Danqi pill (DQP) is one of the most widely prescribed formulas and has been shown to have
remarkable protective effect on coronary heart disease (CHD). However, its regulatory effects on lipid metabolism
disorders haven’t been comprehensively studied so far. We aimed to explore the effects of DQP on Peroxisome
Proliferator activated receptors α (PPARα), lipid uptake-transportation-metabolism pathway and arachidonic acid
(AA)-mediated inflammation pathway in rats with CHD.
Methods: 80 Sprague-Dawley (SD) Rats were randomly divided into sham group, model group, positive control
group and DQP group. Rat model of CHD was induced by ligation of left ventricle anterior descending artery and
fed with high fat diet in all but the sham group. Rats in sham group only underwent thoracotomy. After surgery,
rats in the positive control and DQP group received daily treatments of pravastatin and DQP respectively. At
28 days after surgery, rats were sacrificed and plasma lipids were evaluated by plasma biochemical detection.
Western blot and PCR were applied to evaluate the expressions of PPARα, proteins involved in lipid metabolism
and AA pathways.
Results: Twenty eight days after surgery, dyslipidemia developed in CHD model rats, as illustrated by elevated
plasma lipid levels. Expressions of apolipoprotein A-I (ApoA-I), cluster of differentiation 36 (CD36) and fatty acid
binding protein (FABP) in the heart tissues of model group were down-regulated compared with those in sham
group. Expressions of carnitine palmitoyl transferase I (CPT-1A) and lipoproteinlipase (LPL) were also reduced
significantly. In addition, levels of phospholipase A2 (PLA2) and cyclooxygenase 2 (COX-2) were up-regulated.
Expressions of Nuclear factor-κB (NF- κB) and signal transducer and activator of transcription 3 (STAT3) also increased.
Furthermore, Expression of PPARα decreased in the model group. DQP significantly up-regulated expressions of ApoA-I
and FABP, as well as the expressions of CPT-1A and CD36. In addition, DQP down-regulated expressions of PLA2,
COX-2 and NF-κB in inflammation pathway. Levels of STAT3 and LPL were not affected by DQP treatment. In particular,
DQP up-regulated PPARα level significantly.
Conclusions: DQP could effectively regulate lipid uptake-transportation-metabolism process in CHD model rats, and
the effect is achieved mainly by activating ApoA-I-CD36-CPT-1A molecules. Interestingly, DQP can up-regulate
expression of PPARα significantly. The anti-inflammatory effect of DQP is partly exerted by inhibiting expressions of
PLA2-COX2 -NF-κB pathway.
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Background
Coronary heart disease (CHD) remains one of the major
causes of mortality worldwide, even though great pro-
gress has been made in the development of novel thera-
peutic approaches. Pathological mechanisms of CHD
have been the focus of research and it’s believed that
lipid infiltration and inflammation contribute to CHD
progress [1, 2]. The corresponding anti-inflammatory
and lipid-lowering drugs have been widely applied in the
management of CHD [3–5].
According to lipid infiltration theory of CHD, abnor-
mal deposition of lipid in subendothelial layer of artery
causes narrowing of coronary arteries, which will even-
tually lead to CHD [6]. Studies have shown that high
level of plasma low density lipoprotein (LDL) is an inde-
pendent risk factor for CHD, whereas high level of high
density lipoprotein (HDL) is inversely correlated with
risk of CHD [7, 8]. Apolipoprotein A-I (ApoA-I) is the
major protein component of HDL and is involved in
the transport of cholesterol from circulatory system to the
liver [9]. Lipoprotein lipase (LPL) is the key enzyme in the
catabolism of triglyceride. It breaks down triglycerides into
free fatty acids (FFA), which provide 80 % of the energy
consumed by cardiomyocytes [10]. Plasma FFA are com-
bined with fatty acid-binding protein (FABP) and trans-
ferred into cytoplasm of cardiac cells by cluster of
differentiation 36 (CD36), and then further transported
into mitochondria through carnitine, catalyzed by carniti-
nepalmitoyltransferase I (CPT-I) which is another key en-
zyme in fatty acid metabolism [11, 12]. FFA eventually
undergo oxidation in mitochondria to produce ATP for
heart contraction [13, 14].
In addition to lipid filtration, inflammation also con-
tributes to the initiation and progression of CHD. Ara-
chidonic acid (AA) mediated inflammation is thought to
be the major cause of myocardial cell damage [15].
Under inflammatory stimuli, phospholipase A2 (PLA2)
hydrolyzes phospholipids in cell membranes and releases
AA, which are further converted into active compounds
catalyzed by different subtypes of cyclooxygenases (COXs).
The major metabolic products of AA include prostaglan-
dins (PGs), prostacyclin (PGI2) and thromboxanes (TXBs),
which are involved in inflammatory responses [16, 17].
Therefore, inhibiting AA-mediated PLA2-COX pathway
to protect cardiac cells against inflammatory injuries has
become the strategy for the management of CHD [18].
Nonsteroidal anti-inflammatory drugs (NSAIDs) have
been widely used to treat patients with CHD. However,
there has been an increasing number of reports about car-
diotoxicities induced by NSAIDs [19].
Peroxisome Proliferator activated receptors α (PPARα)
has been found to play crucial roles in regulating lipid
metabolism [20, 21]. Activation of PPARα reduces plasma
level of very low density lipoprotein (VLDL) by inhibiting
synthesis of triglyceride and cholesterol. PPARα also
promotes plasma triglyceride clearance by mobilizing
LPL activity and enhancing oxidation of fatty acids,
thereby regulating plasma lipid levels [22]. In addition,
PPARα also exerts anti-inflammatory effect, mainly
through inhibiting the activity of COX-2 and monocyte
chemoattractant protein-1 (MCP-1) through NF-κB sig-
naling pathway [23, 24]. Therefore, PPARα agonists are
considered to be the promising new candidates for the
treatment of CHD.
Traditional Chinese medicine has been applied in the
treatment of CHD for thousands of years. DQP is one of
the most widely prescribed formulas and has been
shown to have remarkable protective effect on ischemia
heart tissues [25]. DQP is prepared from equal amounts
of two dried Chinese herbs, Salvia miltiorrhiza Bunge
and Panax notoginseng (Burk.) F. H. Chen. The major ef-
fective ingredients of Salvia miltiorrhiza Bunge and
Panax notoginseng (Burk.) F. H. Chen are salvianolic
acids and panax notoginseng saponins (PNS), respect-
ively [26, 27]. DQP was widely produced in China in ac-
cordance with the China Pharmacopoeia standard of
quality control, and was listed in Chinese Pharmacopoeia
2010 as routine drug in the clinical treatment of CHD
[28]. Until now, many studies have been conducted to in-
vestigate the effects of active monomers in DQP on CHD.
PNS were found to inhibit ischemia-induced myocardial
apoptosis and tanshinone IIA (monomer of Salvia miltior-
rhiza) was found to have cardioprotective and anti-
hypertrophic effects [29, 30]. Our previous studies proved
that DQP had efficacy on CHD through regulating Renin-
Angiotensin-Aldosterone System (RAAS) and lipid metab-
olism [31, 32]. However, the comprehensive effects of
DQP on PPARα, lipid metabolism and inflammation path-
way mediated by PLA2-COX-2 haven’t been completely
understood yet. In this study, we aim to investigate the
effects of DQP on lipid metabolism and PLA2-COX-2
pathway, so as to uncover the pharmacological mecha-




Studies were performed in accordance with the Guide
for the Care and Use of Laboratory Animals published
by the National Institutes of Health (NIH Publications
No. 85-23, revised 1996) the China Physiological Society’s
“Guiding Principles in the Care and Use of Animals” and
with approval of the Animal Care Committee of Beijing
Medical Center. A total of 80 male Sprague-Dawley (SD)
rats (weighted 220 g ± 10 g) in Specific Pathogen Free
(SPF) grade were selected (purchased from Beijing Vital
River Laboratory Animal Technology Co.Ltd. License
number: SCXK2010–2011).
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Animal model preparation
Rats were randomly divided into four groups: sham
group, model group, positive control group (control)
and DQP group. CHD rat model with in vivo coronary
left anterior descending (LAD) occlusion was then in-
duced as described in our previous study [32]. Briefly,
left thoracotomy was performed after rats were anaes-
thetized by 1 % pentobarbital sodium at the dosage of
50 mg/kg. LAD coronary artery was then ligated with a
5-0 polypropylene suture. The thorax was closed with
2.0 absorbable silk surgical sutures as we previously re-
ported after ligation. The sodium penicillin was given to
prevent the potential wound inflammation for 3 days
after surgery. Rats in sham group received the same pro-
cedures except that the coronary artery was not ligated.
In addition, rats in model group, positive control group
and DQP group were fed with high fat diet for 28 days
while rats in sham group fed with normal diet. From the
second day after operation, rats in DQP group were
treated with DQP aqueous solution (Tongren tang,
Beijing, China, Series: 6128006) at the daily dosage of
1.5 mg/kg via oral gavage for 28 consecutive days. Rats
in positive control group received pravastatin (Bristol-
Myers Squibb, China, Series: H19980197) aqueous solu-
tion at the daily dosage of 1.2 mg/kg. Animals in sham
group and model group were given a gavage of normal
saline water for 28 days. All animals were anaesthetized
using pentobarbital sodium following an overnight fast
at the end of study. Blood samples were collected via ab-
dominal aorta puncture.
The overall mortality rate of rats during the entire ex-
periment (28 days after surgery) was 22.5 %. Among
them, 7 rats died during the surgery and 11 rats died the
day after the surgery, probably due to acute pump failure
or lethal arrhythmias, as they manifested serious clinical
signs, such as short of breath and severe tachycardia.
Assessment of cardiac functions
Cardiac functions were assessed by echocardiography at
28d after surgery. Rats were anaesthetized before assess-
ment. The parameters of heart functions include: left ven-
tricular end-systolic diameter (LVESd), left ventricular
end-diastolic diameter (LVEDd), ejection fraction (EF) and
fractional shortening (FS). EF was calculated as follows:
EF = [(LVEDv − LVESv)/LVEDv] × 100 %. FS was calculated
using the equation: [(LVEDd − LVESd)/LVEDd] × 100 %.
Measurement of plasma TC, TG, LDL and HDL levels
Twenty eight days after surgery, animals were sacrificed
after anaesthetization and blood was taken through ab-
dominal aorta. The blood was centrifuged at 8000 g for
10 min and supernatant was used for detection of
plasma indicators. Plasma levels of total cholesterol
(TC), triglyceride (TG), high density lipoprotein (HDL)
and low density lipoprotein (LDL) were measured by
automatic biochemical analyzer (HITACH17080, Japan)
following manufacturer’s instructions. The cholesterol
kit (COD-PAP Method), triglyceride kit (GPO-PAP
Method), direct HDL kit and direct LDL kit were pur-
chased from BiosinaTechnologies Inc.
Evaluation of mRNA expressions of molecules involved in
lipid metabolism by polymerase chain reaction (PCR)
Expressions of LPL and CD36 in heart tissues were de-
termined by reverse transcriptase polymerase chain reac-
tion (RT-PCR). Heart tissues near infarct zone were
excised and frozen in liquid nitrogen. Total RNA was ex-
tracted using Trizol Reagent (Gibco-BRL, Paisley, UK).
The concentration of RNA was measured by Nano Drop
2000 (Thermo Scientific, USA). RNA was transcribed
using the RevertAidTM First Stand cDNASynthesis kit
(Fermentas, LT). RNAs quantities of LPL, CD36 and
GAPDH were analyzed by PCR. The reaction system con-
tained 2 μl cDNA, 0.5 μl forward and reverse primers,
10 μl Rox and 7 μl DEPC water. PCR conditions were set
as follows: 15 s at 95 °C for denaturation, 1 min at 55 °C
for annealing and extension. 40 cycles of amplifications
were performed for each gene. The sequences of the
primers were shown at Table 1. Quantities of LPL and
CD36 mRNA were normalized to mRNA quantities of
GAPDH.
Measurement of protein expressions detected by western
blot
The border of infarcted myocardium in left ventricle ho-
mogenates was prepared for the analysis of protein
levels. Equal amounts of protein extracts (20 μg) were
separated by 12.5 % or 15 % sodium dodecyl sulphate
(SDS)-polyacrylamide gel electrophoresis (Bio-Rad, CA,
U.S.A.) and transferred to nitrocellulose membranes
electrophoretically (semidry transfer). Membranes were
blocked with 5 % non-fat dry milk in Tris-buffered saline
(20 mM Tris, pH 7.6, 137 mM NaCl) with 0.1 % Tween
20, washed, and then incubated with primary antibody.
Primary antibodies employed included: goat polyclonal
antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and anti-ApoA-I, PPARα, FABP, CPT-1A, PLA2, COX-2,
Table 1 Nucleotide sequences of primers used in real-time PCR
Gene
(accession no.)




LPL Forward CGCTCCATCCATCTCTTC 57.3
Reverse GGCTCTGACCTTGTTGAT 159 55.0
CD36 Forward GGTCCTTACACATACAGAGT 55.8
Reverse CCACAGCCAGATTGAGAA 163 55.0
GAPDH Forward TCAACGGCACAGTCAAG 55.0
Reverse TACTCAGCACCAGCATCA 116 55.0
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NF-κB and STAT3 (Anti-Apolipoprotein AIantibody,
ab334707, 1:250; Anti-CPT1A,ab128568,1:500;Anti-PPARα
antibody,ab8934,1:1000;Anti-STAT3 antibody, ab76315,
1:250; Anti-Cardiac FABP antibody, ab174673,1:2000;
Anti-Phospholipase A2 Antibody, ab23705, 1:250;Anti-
NF-κB p105/p50 antibody,ab32360,1:500; Anti-COX2,
ab15191,1:500). The primary antibody was firstly incu-
bated, and then the secondary antibodies (Santa Cruz Bio-
technology Inc., CA, U.S.A.) was added. After exposed by
chemiluminescence developing agents, the protein levels
and GAPDH in each sample were evaluated. The gel was
scanned and the band densities were quantified. Protein
expressions were normalized by the GAPDH band dens-
ities and then normalized by density in sham group to de-
termine their concentrations.
Statistical analysis
Data were presented as mean ± standard deviation (mean ±
SD). Differences among groups were analyzed by one-way
analysis of variance (ANOVA) test. P values of smaller
than 0.05 were considered as statistically significant. All
statistical analyses were carried out using SPSS 17.0
software.
Results
Effects of DQP on cardiac functions
Echocardiography results showed that LVEDd and LVESd
in the model group increased by 53.52 % (P < 0.01) and
156.73 % (P < 0.01) as compared with those in the sham
group, respectively (Fig. 1, Table 2). EF and FS in model
group decreased by 49.96 % (P < 0.001) and 58.30 % (P <
0.001) respectively, suggesting that cardiac functions were
severely impaired and CHD model was successfully in-
duced. After treatment with DQP for 28 days, LVESd was
reduced as compared with that in the model group.
LVEDd wasn’t affected by DQP. DQP could elevate the
values of EF and FS by 43.00 % (P = 0.036) and 54.06 %
(P = 0.041), respectively.
Effects of DQP on plasma lipid and lipoprotein levels
Compared with the sham group, levels of TC, TG, LDL
and VLDL in the model group increased by 40.50 %
(P = 0.032), 155.33 % (P = 0.004), 49.07 % (P = 0.031) and
170.52 % (P = 0.002), respectively. HDL level decreased by
46.11 % (P = 0.021) in model group compared with that in
the sham group. After treatment with DQP, TG level ra-
ther than TC level in DQP group was reduced in DQP
group compared with model group, suggesting that DQP
has better efficacy on TG rather than TC. Levels of LDL
and VLDL in the DQP group decreased by31.85 % (P =
0.015) and 56.49 % (P = 0.008) respectively, as compared
with those in the model group. HDL level was up-
regulated by 76.44 % (P = 0.026). These data suggested
that DQP could regulate disorders of lipid metabolism in
rats with CHD. The effects of Pravastatin on plasma lipid
levels were similar with those of DQP (Table 3).
Fig. 1 DQP improved parameters of cardiac functions detected by echocardiography. Echocardiography results showed that LVEDd and LVESd in
the model group increased significantly compared with those in the sham group. EF and FS in model group decreased respectively. DQP could
reduce the LVESd while LVEDd wasn’t affected by DQP. DQP also could upregulate EF and FS respectively, suggesting that DQP could improve
cardiac function (*P < 0.05, **P < 0.01, other groups vs. model group, n = 8). a Cardiac functions in sham-operated group. b Cardiac functions were
down-regulated in model group rats. c Positive Drug had no effects on the cardiac function. d DQP could significantly up-regulate the EF and FS
Chang et al. BMC Complementary and Alternative Medicine  (2016) 16:103 Page 4 of 10
Effects of DQP on key molecules involved in uptake of
lipids
Expressions of LPL and CD36 were down-regulated
by 30.65 % (P = 0.002) and 9.2 % (P = 0.034) in model
group compared with those in the sham group, which
suggested that uptake of FFA by cardiocytes was com-
promised in the model rats. After treatment with
DQP, expressions of CD36 was up-regulated by
15.47 % (P = 0.03), compared with those in the model
group (Table 4). However, DQP showed no effect on
expression of LPL in this study. Pravastatin showed
no effect on the expressions of either LPL or CD36
(Table 4).
Effects of DQP on lipid transportations
Expressions of ApoA-I and FABP in the model group
(0.87 ± 0.04 and 0.90 ± 0.039) were down-regulated by
12.63 % (P = 0.016) and 10.00 % (P = 0.381), respect-
ively, as compared with those in the sham group (1.00 ±
0.00, 1.00 ± 0.00). Level of CPT-1A, the key enzyme
in lipid oxidation, decreased by 28.44 % (0.71 ± 0.064,
P = 0.017) in the model group compared with those in
the sham group (1.00 ± 0.00). Suppressed expressions
of ApoA-I, FABP and CPT-1A suggested that trans-
portation of fatty acids into mitochondria for oxida-
tion was inhibited in CHD rats. In DQP group,
expressions of ApoA-I (1.39 ± 0.081) and FABP (1.16 ±
0.189) were up-regulated by 59.53 % (P < 0.01) and
28.97 % (P = 0.03) respectively, compared with those in
the model group. Expression of CPT-1A also increased by
54.93 % (1.11 ± 0.192, P = 0.001), suggesting that DQP
promoted the transportation of lipid into mitochondria
for oxidation (Fig. 2).
Effects of DQP on inflammation pathway
We then investigated changes of proteins in PLA2-
COX-2 mediated inflammation pathway. Compared with
the sham group (1.00 ± 0.00, 1.00 ± 0.00), expressions of
PLA2 and COX-2 in the model group were up-regulated
by 47.5 % (1.48 ± 0.225, P = 0.002) and 92.54 % (1.93 ±
0.856, P = 0.0196), respectively. DQP was shown to in-
hibit the activation of this pathway. Expressions of PLA2
and COX-2 in DQP group were down-regulated by
25.11 % (1.10 ± 0.225, P = 0.012) and 58.50 % (0.799 ±
0.156, P = 0.0039), compared with those in the model
group. Control drug had no significant effect on the ex-
pression of PLA2 or COX-2 (Fig. 3).
Effects of DQP on PPARα signaling pathway
NF-κB and STAT3 are signal transduction factors that
are important in promoting ventricular hypertrophy.
Compared with the sham group (1.00 ± 0.00, 1.00 ±
0.00), expressions of NF-κB and STAT3 in the model
group were up-regulated by 35.75 % (1.358 ± 0.212, P =
0.074) and 113.9 % (2.14 ± 0.354, P < 0.01), respectively.
Expression of PPARα, the critical regulator of lipid me-
tabolism, was down-regulated by 24.25 % (0.76 ± 0.162,
P = 0.031) in the model group compared with that in the
sham group. After treatment with DQP, NF-κB was
inhibited and PPARα was activated. Expression of NF-κB
was down-regulated by 56.2 % (0.59 ± 0.131, P = 0.0004)
in DQP group compared with that in the model group,
which suggested that the anti-inflammatory effect of
DQP may be mediated by inhibition NF-κB. Compared
with the model group, PPARα level increased by
141.31 % (1.83 ± 0.729, P < 0.001) in DQP group, demon-
strating that DQP is a potent agonist of PPARα (Fig. 4).
DQP showed no effect on STAT3 expression.
Discussion
Traditional Chinese medicine has been widely used in
the prevention and treatment of CHD for thousands of
Table 2 Indicators of cardiac function in different groups
Group Sham Model Control DQP
LVEDd(mm) 5.651 ± 0.849** 8.675 ± 1.335 9.043 ± 1.254 8.812 ± 0.557
LVEDs(mm) 2.755 ± 0.848** 7.073 ± 1.716 6.635 ± 0.769* 6.748 ± 0.677
EF(%) 81.604 ± 7.922** 40.831 ± 19.212 32.327 ± 16.765 58.391 ± 10.623*
FS(%) 51.939 ± 9.322** 21.661 ± 11.782 16.579 ± 9.468 33.372 ± 6.696*
Compared with model group, P < 0.05 *, P < 0.01**
Table 3 Indicators of plasma lipid and lipoprotein levels in
different groups
Group Sham Model Control DQP
TC(mmol/L) 1.49 ± 0.35* 1.49 ± 0.35* 1.49 ± 0.35* 2.24 ± 0.28
TG(mmol/L) 1.05 ± 0.21** 2.68 ± 0.49 0.98 ± 0.51** 1.35 ± 0.37*
HDL(mmol/L) 0.83 ± 0.18* 0.44 ± 0.26 0.97 ± 0.20* 0.78 ± 0.35*
LDL(mmol/L) 0.50 ± 0.13* 0.75 ± 0.20 0.33 ± 0.16** 0.51 ± 0.11*
VLDL(mmol/L) 0.46 ± 0.104** 1.25 ± 0.238 0.45 ± 0.176** 0.54 ± 0.207**
Compared with model group, P < 0.05 *, P < 0.01**
Table 4 Key molecules involved in uptake of lipid in different
groups
Group Sham Model Control DQP
CD36 1.208 ± 0. 026* 1.097 ± 0.068 1.235 ± 0.149 1.267 ± 0.063*
LPL 1.525 ± 0. 159** 1.194 ± 0.247 0.893 ± 0.226 1.158 ± 0.0247
Compared with model group, P < 0.05 *, P < 0.01**
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Fig. 2 Effects of DQP on the myocardial concentrations of ApoA-I, FABP and CPT-1A. The results showed that expressions of ApoA-I and CPT-1A
in the model group decreased compared with those in the sham group. Level of FABP showed no statistical difference between sham and model
group. DQP could increase ApoA-I, FABP and CPT-1A levels. Pravastatin had similar effect as DQP. *indicates P < 0.05, **indicates P < 0.01. Levels in
the model group (n = 6) were used as reference to calculate P values
Fig. 3 Effects of DQP on the myocardial concentrations of PLA2 and COX2. Western blot results showed that compared with the sham group,
expressions of PLA2 and COX-2 in the model group were up-regulated. Expressions of PLA2 and COX-2 in DQP group were down-regulated
significantly, compared with those in the model group. Control drug had no significant effect on the expression of PLA2 or COX-2. *P < 0.05,
**P < 0.01. Protein expression levels in the model group (n = 6) were used as reference to calculate P values
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years [33]. DQP is one of the most commonly prescribed
formulas and has been shown to be effective in treating
CHD [34]. In this study, we investigated the pharmaco-
logical mechanisms of DQP in a rat model of CHD in-
duced by ligation of coronary artery. Our major findings
are as follows: 1), DQP can effectively improve the car-
diac functions and regulate plasma lipids levels in rats
with CHD. 2), DQP promotes lipid oxidation in cardio-
myocytes by up-regulating expressions of molecules
involved in uptake and transportation of lipids, which
include ApoA-I, CD36 and CPT-1A. 3), the anti-
inflammatory effect of DQP may be mediated by its in-
hibition on PLA2-COX-2 pathway. DQP down-regulates
NF-κB expression, without affecting STAT3 expression.
4), DQP has the similar effect with that of PPARα agon-
ist, and activation of PPARα might be the major mech-
anism by which DQP regulates lipid metabolism and
inhibits inflammation.
It is reported that dyslipidemia is a high risk factor for
CHD [35]. Cholesterol, triglycerides, LDL and HDL are
the major components of plasma lipids that play critical
roles in the development of CHD. Total blood choles-
terol and LDL increase CHD risk in an independent
manner [7, 36]. Elevated level of TG affects the process
of reverse cholesterol transportation by HDL [37, 38].
It’s reported that an increase of 23 mg/dl in TG content
will lead to 20 % increased risk of developing CHD [39].
Contrary to the effects of TG and LDL, HDL is considered
to be a protective factor against development of CHD.
High level of HDL is related with decreased risk of CHD
[40]. HDL and its major component, ApoA-I, can pro-
mote reversal cholesterol transport and regress formation
of atherosclerotic plaques [41, 42]. HDL can also inhibit
inflammation by down-regulating expression of vascular
cell adhesion molecule-1 [43]. In this study, we found that
plasma levels of TG, LDL and VLDL increased, while
levels of ApoA-I and HDL decreased in model group. Fur-
thermore, level of lipoprotein lipase (LPL), the key enzyme
in regulating lipid and lipoprotein metabolism, also de-
creased in the model group. Treatment with DQP could
effectively regulate disorders in lipid metabolism, as was
evidenced by decreased plasma levels of TG, LDL and in-
creased HDL level in DQP group compared with the
model group. However, DQP didn’t show effect on expres-
sion of LPL. Positive control drug showed similar effect
on lipids levels as that of DQP. However, positive control
drug failed to improve cardiac functions, indicating that
DQP has advantage over control drug in the treatment of
cardiovascular disease.
The effect of DQP on lipid metabolism pathway was
then examined. Fatty acid translocase/cluster of differen-
tiation protein (FAT/CD36) plays an important role in
lipid metabolism by transporting long chain fatty acid
into mitochondria [44–47]. Overexpression of FAT/
CD36 promotes oxidation of fatty acid and lipoproteins
[48]. Plasma fatty acids are translocated into cytoplasm
Fig. 4 Effects of DQP on the levels of NF-κB, STAT3 and PPARα. Western blot showed that compared with the sham group, expressions of NF-κB
and STAT3 in the model group were up-regulated (P = 0.074, P < 0.01). Expression of PPARα was down-regulated (P = 0.031) in the model group
compared with that in the sham group. DQP could inhibit NF-κB level but showed no effect on STAT3 expression. Pravastatin had no effect on
expression of STAT3 either. Compared with the model group, PPARα level increased in DQP group. *P < 0.05, **P < 0.01. Levels in the model group
(n = 6) were used as reference to calculate P values
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of myocardial cells by binding with fatty acid binding
protein (FABP) on the membrane, and are further trans-
ferred into mitochondria catalyzed by the enzyme CPT-
I. Oxidation of fatty acids in mitochondria provides the
majority of energy for heart contraction and CPT-I is
the critical enzyme in oxidation process [49]. CPT-1A is
one of the most abundant subtypes of CPT-I. In this
study, expressions of FABP, CD36 and CPT-1A in the
heart tissues of model rats were significantly reduced,
which suggested that uptake and transportation of lipids
were deregulated under myocardial ischemic conditions.
The disorder of lipid transportation will lead to build-up
of lipids in the plasma as well as shortage of energy sup-
plies. After treatment with DQP, CD36 and CPT-1A
levels were considerable up-regulated, compared with
those in the model group, demonstrating that DQP has
the effect of promoting lipid uptake by cardiac cells.
In addition to disorders of lipid metabolism, arachi-
donic acids (AA)-mediated inflammation is also an
important pathological mechanism of cardiovascular dis-
eases [25]. We further explored the effect of DQP on in-
flammation pathway. Under normal conditions, most of
theAA exist in membranes as the components of phos-
pholipids. When cell is under ischemic or inflammatory
stimuli, phospholipid lipase A2 (PLA2) will catalytically
hydrolyse phospholipids and release AA into cytoplasm.
AA are subsequently converted to different metabolites
by a series of enzymes. COXs are a group of enzymes
that convert AA into prostaglandins (PGs) and throm-
boxanes (TXs), which are the major best-known prod-
ucts of AA. PGs and TXs mediate myocardial damage,
apoptosis, fibrosis and progression of CHD [50]. There-
fore, inhibiting activities of COXs has become a new
strategy for the management of CHD [18]. Studies have
shown that selective COX-2 inhibitors can inhibit vascu-
lar inflammation, reduce monocyte infiltration, increase
production of NO, attenuate atherosclerosis and stabilize
plaques, thereby reducing incidence of cardiovascular
events [51]. COX-2 inhibitors can also improve cardiac
function under myocardial infarction conditions [18]. In
this study, we found that AA-mediated inflammation
pathway was activated in the model group, as both
PLA2 and COX-2 were over-expressed in ischemic heart
tissues. DQP treatment significantly inhibited expres-
sions of PLA2 and COX-2, indicating that DQP has both
lipid-lowing and anti-inflammatory effects.
DQP also exerts its cardioprotective effects by acting
on PPARα. There are three subtypes of PPAR: α, β(δ)
and γ [52]. PPARα is mainly expressed in metabolically
active tissues, such as heart, liver, kidney, etc. As a
Fig. 5 Potential mechanism of DQP efficacy on CHD rats. DQP has regulatory effect on lipid uptake-transport-metabolism pathway in myocardial
cells of rats with heart failure. Moreover, DQP can up-regulate expression of PPARα significantly. The anti-inflammatory effect of DQP is probably
achieved by inhibiting NF-κB in PLA2-COXs mediated inflammation pathway
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important regulator of metabolism, PPARα has a central
coordinating role in the regulation of fatty acid oxida-
tion, lipoprotein metabolism, inflammation and vascular
responses [53–55]. It was reported that under myocar-
dial ischemic circumstances, mRNA expression of
PPARα was reduced and FFA uptake was decreased,
aggravating cardiac ischemic damage [56]. All these evi-
dences support a linkage between PPARα and cardiovas-
cular diseases. PPARα also exerts anti-inflammatory
effect by inhibiting NF-κB mediated pathway and down-
regulating secretion of pro-inflammatory factors, such as
IL-6, TNF-α and COX-2 [57]. Our study showed that in
ischemic heart tissue, expression of PPARα was down-
regulated and expressions of COX-2 and NF-κB were
up-regulated, indicating that inflammation pathway was
activated under ischemic conditions. DQP can effectively
inhibit inflammation by reducing expressions of NF-κB
and COX-2. More importantly, PPARα expression was
significantly up-regulated in DQP-treated group com-
pared with the model group, demonstrating that DQP
is a potential effective PPARα agonist in the treat-
ment of CHD.
Conclusions
DQP has regulatory effect on lipid uptake-transport-
metabolism pathway in myocardial cells of rats with heart
failure, and the effect is achieved mainly by activating
ApoA-I-CD36-CPT-1A molecules. The anti-inflammatory
effect of DQP is probably achieved by inhibiting NF-κB in
PLA2-COXs mediated inflammation pathway (Fig. 5).
Interestingly, DQP can up-regulate expression of PPARα
significantly. This study provides experimental evidence for
the clinical application of DQP in the treatment of CHD.
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